Company intelligence / Profile preview

PulseOn

Ownership: Private
Development stage: Commercial

Overview

PulseOn has developed and commercialized a CE-certified wearable solution for continuous, beat-to-beat optical heart rate monitoring combined with intermittent ECG. Clinical results published in 2023 demonstrated reliable outpatient atrial fibrillation detection using their wrist-worn device. The system enables long-term, non-intrusive monitoring of asymptomatic and short-duration arrhythmic episodes.

Therapeutic areas: Cardiovascular
Modalities: DeviceWearable medical device
Industry: Physiological Monitoring

Partnerships

Collaborations with cardiologists for product development and validationBoard member from University Hospital Basel indicating academic/clinical partnership

Beyond the preview

Go deeper on PulseOn.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PulseOn.

Explore the full profile